Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1992-9-14
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0362-5664
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
15 Suppl 1 Pt A
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
470A-471A
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:1354053-Dopamine,
pubmed-meshheading:1354053-Dopamine Agents,
pubmed-meshheading:1354053-Humans,
pubmed-meshheading:1354053-Receptors, Dopamine,
pubmed-meshheading:1354053-Receptors, Dopamine D2,
pubmed-meshheading:1354053-Schizophrenia,
pubmed-meshheading:1354053-Tomography, Emission-Computed
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
In vivo assessment of dopaminergic variables in schizophrenia.
|
| pubmed:affiliation |
SHFJ-CEA, Orsay, France.
|
| pubmed:publicationType |
Journal Article
|